Zdeněk Dvořák, Pavel Starha, Zdeněk Trávníček
Regional Centre of Advanced Technologies and Materials, Department of Cell Biology and Genetics, Faculty of Science, Palacký University, 17. listopadu 12, 771 46 Olomouc, Czech Republic. moulin@email.cz
Toxicology in vitro : an international journal published in association with BIBRA 2011 AprA series of seven platinum(II) cyclobutane-1,1-dicarboxylato (cbdc) complexes {[Pt(cbdc)(L(n))(2)], 1-7}, derived from carboplatin by a substitution of two NH(3) molecules for two 2,6,9-trisubstituted 6-benzylaminopurine-based N-donor ligands (L(n)), was studied by the MTT assay for their in vitro cytotoxic activity against seven human cancer cell lines, i.e. lung carcinoma (A549), cervix epithelioid carcinoma (HeLa), osteosarcoma (HOS), malignant melanoma (G361), breast adenocarcinoma (MCF7), ovarian carcinoma (A2780) and its cisplatin-resistant analogue (A2780cis), and against two primary cultures of human hepatocytes (LH31 and LH32). The prepared complexes were cytotoxic against several cancer cells, in some cases even more than cisplatin. The best results were achieved for complexes 1 (IC(50)=17.4 ± 2.0 μM) and 2 (IC(50)=14.8 ± 2.1 μΜ) against HOS cells, 1 (IC(50)=15.1 ± 6.8 μM), 2 (IC(50)=13.6 ± 5.2 μM) and 6 (IC(50)=19.0 ± 6.6 μM) against MCF7, 6 (IC(50)=6.4 ± 0.1 μM) against A2780, and 1-6 (IC(50)=15.6 ± 4.0, 12.9 ± 3.7, 15.8 ± 3.8, 16.6 ± 5.5, 22.1 ± 2.5, and 5.6 ± 1.7 μM, respectively) against A2780cis. Viability of human hepatocytes was not declined by the tested complexes up to the concentration of 50 μM (for 1, 3-7) and 20 μM (for 2; caused by lower solubility of this complex). Copyright © 2011 Elsevier Ltd. All rights reserved.
Zdeněk Dvořák, Pavel Starha, Zdeněk Trávníček. Evaluation of in vitro cytotoxicity of 6-benzylaminopurine carboplatin derivatives against human cancer cell lines and primary human hepatocytes. Toxicology in vitro : an international journal published in association with BIBRA. 2011 Apr;25(3):652-6
PMID: 21232594
View Full Text